An in vitro model simulating two-compartment pharmacokinetics was used to study the antibacterial activity of lomefloxacin after single oral doses of 200 and 400 mg. Lomefloxacin produced reliable bactericidal activity against gram-negative aerobic bacteria and staphylococci. Bacterial strains for which MICs were <0.5 ,ug/ml were inhibited with both dosing schedules. Doubling the dose from 200 to 400 mg increased the bactericidal activity only against Pseudomonas aeruginosa. Against Enterococcus faecalis lomefloxacin showed no effect.
activity only against Pseudomonas aeruginosa. Against Enterococcus faecalis lomefloxacin showed no effect.
Selection of resistant variants during the simulation of treatment was observed with Staphylococcus aureus and P. aeruginosa.
Lomefloxacin is a new difluorinated quinolone with a broad spectrum of antibacterial activity. Its in vitro activity is similar to those of norfloxacin and enoxacin against gram-negative bacteria, but it has relatively weak activity against Enterococcus faecalis (2) . The pharmacokinetic properties of this drug include good oral absorption and a prolonged serum elimination half-life ranging from 7 to 8 h in human volunteers (4) .
The antibacterial activity of antibiotics in vitro is most commonly assessed by determination of the MIC in cultures in which bacteria are exposed to constant concentrations of the substances for about 18 h. In vivo, however, antibiotic concentrations change according to the pharmacokinetics of the particular drug (7) . Therefore, the therapeutic value of antibacterial agents cannot be judged by MIC data alone or by comparison of MICs with pharmacokinetic data. A more reliable judgment can be given by in vitro models, which permit bactericidal activity to be measured under concentrations that appear to occur in vivo (9) .
In this study, we compared the activity of two different doses of lomefloxacin against gram-negative and gram-positive bacteria, simulating the concentration-time curves obtained in humans after single oral doses of 200 or 400 mg.
MATERIALS AND METHODS
For simulation of the concentration-time curves of lomefloxacin, we used the in vitro model of Grasso et al. (3) Table 2 . The central compartment was inoculated with an overnight culture to obtain exponentially growing bacteria at 107 CFU/ml after 1 h of incubation when treatment was started. Samples were drawn at 1-h intervals for bacterial counts and drug concentration measurements. Bacteria were counted by making 10-fold dilutions of the samples with sterile, chilled 0.9% NaCl solution and then plating 50 RI on China blue-lactose agar. To determine bacterial counts below 103 CFU/ml, 1-ml samples were filtered through a 0.2-,um-pore-size filter (type SM 11407, size 47; SartoriusMembranfilter GmbH, Gottingen, Federal Republic of Germany) and cultured on agar. Plates and filters were read after sufficient incubation time to develop colonies at 37°C. The concentrations were determined by an agar diffusion test with Iso-Sensitest agar as the test medium and Klebsiella pneumoniae (CR1) as the indicator organism. Standards were prepared by using Iso-Sensitest broth. Plates were incubated overnight at 37°C, and then inhibition zones were measured. The lomefloxacin assay was linear over a range of 0.125 to 1 ,ug/ml; the coefficient of variation was 5.7% at 0.125 ,ug/ml, 7.5% at 0.25 ,ug/ml, 4.06% at 0.5 jig/ml, and 1.58% at 1 ,ug/ml. The MIC for the bacterial strains was determined by the microdilution method with an inoculum of 105 CFU/ml (5) taken from samples at time zero and after 24 h ( Table 2) .
The 
RESULTS
Drug concentrations. The concentrations of lomefloxacin measured during the experiments correlated well with the data from human volunteers. We did not find a significant difference between the calculated human plasma concentration curve and the periodically determined concentrations in the system (Fig. 1) .
Antibacterial effect. While the nalidixic acid-resistant (NxD) strain of Escherichia coli was not inhibited by the 200-mg dosage, Enterobacter cloacae, Serratia marcescens, K. pneumoniae, and the nalidixic acid-susceptible strain of E. coli were rapidly reduced in numbers by 4 to 6 orders of magnitude (Fig. 2) . The inhibited strains did not show any regrowth until 12 h. K. pneumoniae and the nalidixic acidsusceptible strain of E. coli remained 3 to 4 orders of magnitude below the inoculum at 24 h. The bacterial count of E. cloacae and S. marcescens increased after 12 h and reached counts above the inoculum after 24 h. The doubling of the dose to 400 mg resulted in similar reductions in bacterial cell counts (Fig. 3) by an increase of the dose (Fig. 4) . While E. faecalis was not inhibited at all, the bacterial cell count of Staphylococcus aureus was slowly but continuously reduced by 4 From the AAC data shown in Table 3 , we conclude that an increase of the dose of lomefloxacin from 200 to 400 mg dose not significantly improve its activity against members of the Enterobacteriaceae and S. aureus. Slight differences in the ACC values are within the error of the experiment. Obviously, the 200-mg dose already has the optimum effect for the above-mentioned strains. The 400-mg dose increased the AAC value for P. aeruginosa from 11.42 to 27.47. Another doubling of the dose to 800 mg further increased the effect to 30.13 (data not shown). During the simulation of lomefloxacin treatment, we did not select resistant variants when members of the Enterobacteriaceae were used (Table 2) . However, at both doses we selected resistant strains of S.
aureus. For these, which were cultured at the end of the experiment, the MIC increased fourfold. Similarly, the MIC for P. aeruginosa increased 16-fold after its exposure to the 400-mg dose. The concentration of lomefloxacin during the 200-mg dose is below the MIC for the P. aeruginosa strain. Therefore, regrowth occurs without selection of resistant variants with the lower dose.
The high increase of the MIC (16-fold) of quinolones suggests that the mutation is the result of a point mutation of the gryA gene. Further support comes from MIC data with P-lactam antibiotics and aminoglycosides, since it has been shown that penetration mutants usually have a parallel increase in the MIC of all these antibiotics (6) . The MICs for the lomefloxacin-resistant strains were identical to the MICs of these antibiotics compared with the susceptible strain (MIC of gentamicin, 2 ,ug/ml; and MIC of piperacillin, 4 ,ug/ml).
Lomefloxacin has relatively weak activity, like norfloxacin and enoxacin, against enterococcal and streptococcal species (2) . Against E. faecalis it shows no effect. The bactericidal activity of lomefloxacin against the nalidixic acid-resistant strain of E. coli is similar to that of enoxacin after a single oral dose of 200 mg (B. Wiedemann, Proc. 15th Int. Congr. Chemother., abstr. no. 9, 1987) .
In vitro and in vivo experiments have demonstrated that lomefloxacin has a broad antibacterial spectrum with particularly good activity against gram-negative aerobic bacteria and staphylococci. The MICs for 90% of strains tested of most members of the Enterbacteriaceae are -1 ,ug/ml (8 
